Edition:
India

Hansa Biopharma AB (HNSA.ST)

HNSA.ST on Stockholm Stock Exchange

145.00SEK
15 Nov 2019
Change (% chg)

-1.90kr (-1.29%)
Prev Close
146.90kr
Open
148.00kr
Day's High
148.80kr
Day's Low
143.20kr
Volume
81,623
Avg. Vol
162,759
52-wk High
318.80kr
52-wk Low
116.40kr

Latest Key Developments (Source: Significant Developments)

Hansa Biopharma Divests Its Equity Holding In Genovis
Monday, 15 Apr 2019 

April 15 (Reuters) - Hansa Biopharma AB ::HANSA BIOPHARMA DIVESTS ITS EQUITY HOLDING IN GENOVIS.TRANSACTION GENERATED GROSS PROCEEDS OF SEK 89 MILLION (C.$9.6 MILLION).  Full Article

Hansa Biopharma Appoints Donato Spota As New CFO
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Hansa Biopharma AB ::HANSA BIOPHARMA APPOINTS DONATO SPOTA AS NEW CHIEF FINANCIAL OFFICER.EVA-MARIA JOED, CURRENTLY SERVING AS CFO, WILL CONTINUE IN COMPANY AS VICE PRESIDENT, FINANCE & ADMINISTRATION.  Full Article

Hansa Medical Gets Positive Feedback On Data Generated On Imlifidase
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Hansa Biopharma AB ::HANSA MEDICAL AB PROVIDES REGULATORY UPDATE FOR IMLIFIDASE IN KIDNEY TRANSPLANTATION.PROVIDED AN UPDATE FOLLOWING REGULATORY INTERACTIONS WITH EMA AND FDA FOR IMLIFIDASE IN KIDNEY TRANSPLANTATION.SAYS BOTH AGENCIES PROVIDED POSITIVE FEEDBACK ON DATA GENERATED ON IMLIFIDASE TO DATE.  Full Article

EGM Resolves To Change Hansa Medical's Company Name To Hansa Biopharma
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Hansa Medical AB ::BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF HANSA MEDICAL AB (PUBL).EXTRAORDINARY GENERAL MEETING RESOLVED TO CHANGE HANSA MEDICAL'S COMPANY NAME TO HANSA BIOPHARMA AB.  Full Article

Hansa Medical Receives Positive Opinion For Orphan Drug Designation In The EU
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Hansa Medical AB ::HANSA MEDICAL RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EU FOR IMLIFIDASE FOR ANTI-GBM DISEASE.  Full Article

Hansa Medical: FDA Fast Track Designation For Imlifidase For Transplantation
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Hansa Medical AB ::HANSA MEDICAL RECEIVES FDA FAST TRACK DESIGNATION FOR IMLIFIDASE FOR TRANSPLANTATION.  Full Article

Hansa Medical Reports Positive Final Top Line Results From Two Phase 2 Studies Of Imlifidase For Kidney Transplantation
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Hansa Medical AB ::HANSA MEDICAL REPORTS POSITIVE FINAL TOP LINE RESULTS FROM TWO PHASE 2 STUDIES OF IMLIFIDASE FOR KIDNEY TRANSPLANTATION.SAYS IMLIFIDASE MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN BOTH STUDIES.SAYS TREATMENT WITH IMLIFIDASE ENABLES HIGHLY SENSITIZED PATIENTS TO RECEIVE LIFESAVING TRANSPLANTS.HANSA MEDICAL PLANS TO SUBMIT BLA AND MAA FILINGS IN Q4 2018 OR Q1.RESULTS DEMONSTRATE FAVORABLE SAFETY PROFILE AFTER SIX-MONTH FOLLOW-UP.  Full Article

Hansa Medical Q2 Operating Loss Widens To SEK 58.8 Million
Thursday, 19 Jul 2018 

July 19 (Reuters) - Hansa Medical AB ::Q2 NET REVENUE SEK 0.9 MILLION VERSUS SEK 0.7 MILLION YEAR AGO.Q2 OPERATING LOSS SEK 58.8 MILLION VERSUS LOSS SEK 44.9 MILLION YEAR AGO.  Full Article

Hansa Medical: IdeS Receives Orphan Drug Designation From FDA
Monday, 9 Jul 2018 

July 9 (Reuters) - Hansa Medical AB ::HANSA MEDICAL LEAD CANDIDATE IMLIFIDASE (IDES) GRANTED ORPHAN DRUG DESIGNATION BY THE FDA FOR ANTI-GBM ANTIBODY DISEASE.  Full Article

Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million
Wednesday, 25 Apr 2018 

April 25 (Reuters) - HANSA MEDICAL AB ::Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO.Q1 NET SALES SEK 588,000 VERSUS SEK 1.1 MILLION YEAR AGO.  Full Article